Starpharma Holdings Limited stock analysis
Want to see AU:SPL full AI Analyst Report?
Starpharma Holdings Limited (SPL) Share Price & Analysis
SPL Stock Chart & Stats
- Day’s Range
- AUD 0.42 - AUD 0.44
- 52-Week Range
- AUD 0.31 - AUD 0.88
- Previous Close
- AUD 0.43
- Volume
- N/A
- Average Volume (3M)
- 1.83M
- Market Cap
- AUD 205.24M
- Enterprise Value
- AUD 284.34M
- Total Cash (Recent Filing)
- AUD 11.02M
- Total Debt (Recent Filing)
- AUD 707.00K
- Price to Earnings (P/E)
- ―
- Beta
- 1.68
- Next Earnings
- Mar 02, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Lower Leverage
Debt has fallen from A$8.3m in 2023 to A$0.7m in 2026, materially reducing leverage and financial risk. This gives Starpharma greater balance-sheet flexibility than before while it works toward profitability and manages ongoing development requirements.
Improving Cash Burn
Operating cash flow improved to -A$3.2m and free cash flow to -A$3.5m in 2026, a notable reduction in burn from prior years. Although cash generation remains negative, sustained improvement could extend funding runway and reduce capital pressure.
Gross Profit Generation
Starpharma reported A$12.1m of revenue and A$10.4m of gross profit in 2026, showing that its commercial activities generate substantial gross contribution. That base can support investment in the platform, although operating and net losses remain.
Bears Say
Persistent Operating Losses
EBIT and EBITDA have been negative across all years shown, while 2026 net income was -A$7.5m. Persistent operating losses indicate the business has not yet reached breakeven, limiting internally funded reinvestment and requiring future performance improvement.
Negative Free Cash Flow
Operating cash flow and free cash flow are negative every year shown, with 2026 still at -A$3.2m and -A$3.5m respectively. Continued cash outflows mean Starpharma is not self-funding and may require additional funding unless profitability improves.
Eroding Equity Base
Stockholders’ equity declined from A$62.3m in 2021 to A$13.8m in 2026, while total assets also fell materially. This erosion reduces the balance sheet’s capacity to absorb further losses and constrains flexibility for development and commercialization.
Starpharma Holdings Limited News
SPL FAQ
What was Starpharma Holdings Limited’s price range in the past 12 months?
What is Starpharma Holdings Limited’s market cap?
When is Starpharma Holdings Limited’s upcoming earnings report date?
How were Starpharma Holdings Limited’s earnings last quarter?
Is Starpharma Holdings Limited overvalued?
Does Starpharma Holdings Limited pay dividends?
What is Starpharma Holdings Limited’s EPS estimate?
How many shares outstanding does Starpharma Holdings Limited have?
What happened to Starpharma Holdings Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Starpharma Holdings Limited?
What is the TipRanks Smart Score and how is it calculated?
Starpharma Holdings Limited Stock Smart Score
Company Description
Starpharma Holdings Limited
Starpharma Holdings Limited is a biopharmaceutical enterprise focused on the research, development, and global commercialization of dendrimer-based products for the pharmaceutical, life sciences, and other industries. Its current offerings include VivaGel, a non-antibiotic treatment and preventative measure for bacterial vaginosis. The company also provides the antiviral VivaGel condom and VIRALEZE, an antiviral nasal spray. Furthermore, Starpharma is actively progressing its DEP (dendrimer drug delivery) technology platform. This platform supports multiple oncology candidates in clinical development, such as DEP docetaxel (Phase 2), DEP cabazitaxel (Phase 2), DEP gemcitabine (Phase 1/2), and DEP irinotecan (Phase 2), all aimed at treating cancer. The DEP technology is also being applied to radiotheranostics for cancer diagnosis and therapy, Antibody Drug Conjugates (including DEP HER-2 ADC), and non-oncology programs. Additionally, DEP AZD0466 is currently in Phase 1/2 clinical trials for haematological malignancies. Founded in 1996, the company maintains its headquarters in Abbotsford, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Cheryl Maley
- Employees
- 50
- Website
- starpharma.com
- Address
- Suite 3.02, Richmond, VIC, 3121, AU
Starpharma Holdings Limited (SPL) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 4 | 16 |
| Technical Analysis | 2 | 4 | 4 |
| Moving Averages | 0 | 0 | 12 |








